The global Eosinophilic Granulomatosis with Polyangiitis Treatment Market is currently valued at USD 173.8 Million in 2023 and is anticipated to expand at a CAGR of 5.2%. Owing to the technological advances in healthcare the market is likely to propel to USD 288.5 million by 2033.
The presence of a strong product pipeline and the imminent launches are likely to drive the growth of the Eosinophilic Granulomatosis with Polyangiitis Treatment Market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 173.8 Million |
| Projected Forecast Value (2033) | USD 288.5 Million |
| Global Growth Rate (2023 to 2033) | 5.2% CAGR |
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome, is a form of a vasculitis-a family of rare diseases characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. EGPA is one of the rarest forms of vasculitis and primarily affects the small blood vessels. Individuals diagnosed with EGPA usually have a history of asthma or allergies.
EGPA can affect the lungs, sinuses, skin, heart, intestinal tract, kidneys, nerves, and other organs. EGPA is known as ANCA-associated vasculitis, referring to a blood protein (anti-neutrophil cytoplasmic antibody) that attacks the body’s own cells and tissues. Other forms of ANCA-associated vasculitis include granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The detection of ANCA in the blood can support a diagnosis of EGPA in some patients.
Treatment typically includes corticosteroids such as prednisone used in combination with medications that suppress the immune system. A new medication has been added to the treatment toolbox. In late 2017, the USA Food and Drug Administration (FDA) approved the use of the biological drug mepolizumab (Nucala) for the treatment of EGPA in adults in the United States.
EGPA is considered extremely rare, with an incidence in the United States of 1 to 3 cases per 100,000 adults per year. The international incidence of EGPA is estimated at 2.5 cases per 100,000 adults per year.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Growing Incidences of Churg Strauss Syndrome to Drive the Market Growth
With a significant rise in the number of eosinophils, which affects the immune system. With a tremendous rise, the condition affects the organs of the human body, resulting in a severe and fatal condition, if not treated. As a result, a large number of medications and therapeutics are available across the globe to treat this condition, which is expected to encourage the growth of the global eosinophilic granulomatosis with polyangiitis treatment market in the next few years.
The growing occurrences of church Strauss syndrome and other allergic reactions and asthma, the rising geriatric population, and growing incidences of church Strauss syndrome in children are expected to drive the growth of the market during the assessment period.
The rising focus of the prominent players operating in the global eosinophilic granulomatosis with polyangiitis treatment market on the development of new and effective treatments and the increasing expenditure on research and development activities are projected to accelerate the growth of the overall market in the next few years. Furthermore, the rising support from government organizations and the development of healthcare facilities and infrastructure are projected to supplement the development of the overall market in the forecast period.
Increasing Research & Development Activities to Boost The Market Growth
The increasing awareness among patients regarding this condition and the availability of effective therapeutics are projected to bolster the eosinophilic granulomatosis with polyangiitis treatment market in developed economies
Increasing government expenditure for sinus pain and inflammation, a large number of people visiting doctors for allergic reaction problems,s and an increase in research and development activities are likely to create various new opportunities that will impact eosinophilic granulomatosis with polyangiitis treatment market growth in the forecast period of 2023 to 2033.
The development of modern therapeutics and the increasing number of players with a strong drug pipeline is considered the key factors that are likely to contribute substantially towards the development of the global eosinophilic granulomatosis with polyangiitis treatment market in the next few years.
Lack of Awareness Regarding Eosinophilic Granulomatosis with Polyangiitis Restrain the Market Growth
One of the major factors hindering the growth of the eosinophilic granulomatosis with polyangiitis treatment market over the analysis period includes the lack of awareness regarding the disease. The high cost of therapeutics is another factor that is expected to impede the market growth.
The lack of knowledge and the absence of required healthcare infrastructure are estimated to restrict the growth of the market, particularly in developing economies in the next few years.
The unfavorable reimbursement scenario in many developing countries and the lack of awareness regarding autoimmune disorders in people can hinder the growth of the market during the forecast period. Also, no specific tests available for diagnosis of eosinophilic granulomatosis with polyangiitis can challenge the growth of the target market in the above-mentioned forecast period.
Advancement in Healthcare to Boost the Market Growth in Region
North America dominates the eosinophilic granulomatosis with polyangiitis treatment market with a CAGR of 5.1% in 2023. The market growth in this region is attributed to the increasing number of asthma patients, changes in environmental conditions, increasing allergic reactions, and others. Moreover, the increasing incidence of asthma in the aging population is expected to fuel the growth of the market in this region.
The growing prevalence of autoimmune diseases and endocrine disorders is the primary factor driving the growth of these regions. The rising awareness regarding the malignant effects of eosinophilic granulomatosis with polyangiitis and the development of modern therapies for its treatment and drug approvals are providing a fillip to the market in these regions.
For instance, Roche announced that the USA Food and Drug Administration (FDA) has approved Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients 2 years of age and older. GPA and MPA are rare, potentially life-threatening diseases affecting small and medium-sized blood vessels.
Improvement in healthcare spending propelling the growth of Eosinophilic Granulomatosis with Polyangiitis Treatment in Asia Pacific
Asia-Pacific is anticipated to be the fastest-growing market owing to the growing prevalence of immunosuppressant disease and hyper-eosinophilia-related problems in developing countries and increasing incidences of granulomatosis.
Asia Pacific is expected to witness tremendous growth during the forecast period, due to favorable reimbursement policies and the presence of policies that offer tax benefits. Factors such as expanding the patient base, improving healthcare infrastructure, and increasing the incidence of anemia are also influencing the growth of the region positively.
Country-wise Forecast CAGRs for the Eosinophilic Granulomatosis with Polyangiitis Treatment Market
| United Kingdom | 5.0% |
|---|---|
| India | 4.9% |
| South Korea | 4.5% |
| China | 4.8% |
| United States of America | 5.1% |
Hospital Pharmacy Segment Remains Dominant Among Other Types
The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 35.7%. The growth of the segment is attributed to the increasing prevalence of church Strauss syndrome and hospitalization for treatment.
Hospital pharmacies preserve the stock of products related to eosinophilic granulomatosis with polyangiitis for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the eosinophilic granulomatosis with polyangiitis treatment market.
Some of the start-ups in the eosinophilic granulomatosis with polyangiitis treatment market include-
Some of the key players present in the global eosinophilic granulomatosis with polyangiitis treatment markets are Genentech Inc., F. Hoffmann-La Roche AG, Cephalon Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Sanofi S.A., Koninklijke DSM N.V, AstraZeneca, Novartis International AG, GlaxoSmithKline LLC, Baxter Healthcare Corporation and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR 5.2% from 2023 to 2033 |
| Expected Market Value (2023) | USD 173.8 Million |
| Projected Forecast Value (2033) | USD 288.5 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Regions |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Genentech Inc; F. Hoffmann-La Roche AG; Cephalon Inc.; Teva Pharmaceutical Industries Ltd.; Amgen Inc.; Sanofi S.A.; Koninklijke DSM N.V; AstraZeneca; Novartis International AG; GlaxoSmithKline LLC; Baxter Healthcare Corporation |
| Customization | Available Upon Request |
The projected CAGR of the market by 2033 is 5.2%.
The projected market value for 2033 is USD 288.5 million.
The market is estimated to secure a valuation of USD 173.8 million in 2023.
The healthcare industry is the key consumer of the market.
The market is growing due to the increasing availability of effective treatments.
| Market Size, 2024 | USD 14,511 million |
|---|---|
| Projected Market Size, 2034 | USD 48,396 million |
| Value-based CAGR (2024 to 2034) | 12.8% |
| Expected Market value in 2023 | USD 1.2 Billion |
|---|---|
| Projected Market Value in 2033 | USD 2.1 Billion |
| CAGR (2023 to 2033) | 5.6% |
Explore Therapy Area Insights
View Reports
Eosinophilic Granulomatosis with Polyangiitis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
